Ranbaxy CEO Arun Sawhney On “Thrilling” Days Of Atorvastatin Approvals – An Exclusive Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
You may also be interested in...
Ranbaxy Sees "Progress" On Discussions With U.S. FDA, DOJ; Keeps Lipitor Launch Hopes Alive
MUMBAI - After staying non-committal for several months, Daiichi-Sankyo controlled Ranbaxy Laboratories Ltd. now says it has engaged in wide-ranging negotiations with U.S. FDA and the Department of Justice on multiple issues related to the alleged violation of good manufacturing practices at two of its India-based sites in Paonta Sahib and Dewas
As Launch Date Nears, Is Ranbaxy Exploring Talks To Monetize Lipitor First-launch Opportunity With Generic Rivals?
MUMBAI - As Ranbaxy struggles to deal with U.S. FDA allegations of GMP violations and data falsification at its two Indian manufacturing sites - Paonta Sahib and Dewas - clouds are gathering over its ability to launch a generic equivalent of the planet's largest drug brand Lipitor (atorvastatin) in the United States, about a year from now
U.S. FDA Nails Ranbaxy On Charges Of Falsifying Data; Halts All Application Reviews From Paonta Sahib Plant
MUMBAI - India's largest drug maker Ranbaxy received a body blow after the U.S. Food and Drug Administration initiated a new regulatory action against the company's Paonta Sahib-based manufacturing plant in India. The drug regulator halted review of drug applications from the manufacturing plant due to evidence of falsified data and invoked the Application Integrity Policy